Photocure ASA · OSL:PHO

Photocure ASA — Q2 2002 Earnings Presentation

22 slides from Photocure ASA's earnings presentation, August 2002

  1. Slide 1: PhotoCure ASA Results 2nd quarter 2002

    PhotoCure ASA Results 2nd quarter 2002 August 2002

  2. Slide 2: Highlights

    Highlights „ Metvix® – Commercialisation on track – Positive clinical data in treatment of nodular BCC achieved in US „ Hexvix® – On track for filing of marketing authorisation first half 2003 „ Benzvix® – Clinical pilot studies on track „ AlpharadinTM – PhotoCure has acquired shares and share optio

  3. Slide 3: Marketing Metvix - Number of clinics

    Marketing Metvix® –Commercialisation in the Nordic area on track Clinics with PhotoCure lamps 100 Number of clinics 80 Finland 60 Denmark 40 Norway Sweden 20 0 Febr. 02 May 02 Aug. 02

  4. Slide 4: Marketing Metvix - Number of light sources

    Marketing Metvix® –Commercialisation in the Nordic area on track Number of light sources 140 120 100 Finland 80 Denmark 60 Norway 40 Sweden 20 0 Febr. 02 May 02 Aug. 02

  5. Slide 5: Marketing Metvix - Commercialisation in Sweden

    Marketing Metvix® –Commercialisation in Sweden „ Regulatory approval June 2001 „ Reimbursed price of 1300 SEK per tube of Metvix® October 2001 „ Procedure fee negotiations ongoing „ Target group: 120 dermatology centres „ Training personnel from 78 centres – 46 centres completed – 32 centres to be t

  6. Slide 6: Marketing Metvix - Commercialisation in Norway

    Marketing Metvix® –Commercialisation in Norway „ National approval February 2002 „ Approved price of 1100 NOK per tube of Metvix® „ Reimbursement application filed for Metvix® „ Target group: 85 dermatology centres „ Provided 34 centres with 50 light sources „ Training of centres ongoing

  7. Slide 7: Marketing Metvix - Commercialisation in Denmark

    Marketing Metvix® –Commercialisation in Denmark „ Metvix® commercially available July 2002 „ Single patient reimbursement available „ Procedure fee negotiations ongoing „ Metvix® priced at 1100 DKK per tube „ Target group: 90 dermatology centres „ Market introduction symposium held in May „ Training

  8. Slide 8: Marketing Metvix - Commercialisation in Finland

    Marketing Metvix® –Commercialisation in Finland „ National approval May 2002 „ Target group: 100 dermatology centres – 5 University hospitals established „ Reimbursement application filed for Metvix® „ Metvix® priced at 148 Euro per tube „ Market introduction symposium held in May „ Training of cent

  9. Slide 9: Metvix - Marketing Authorisations in several countries

    Metvix® – Marketing Authorisations in several countries „ National authorisations issued in: – Sweden, Norway, Denmark, Finland, Iceland, Germany, UK, Ireland, Luxembourg, Greece, New Zealand „ Awaiting national authorisations in: – Belgium, Austria, Spain, Italy „ Application pending in Switzerland

  10. Slide 10: Metvix - Strong clinical data achieved in USA

    Metvix® – Strong clinical data achieved in USA Nodular BCC complete response rate 100 % 90 % 80 % 70 % 60 % 50 % 40 % 30 % 20 % 10 % 0% All areas Facial lesions Lesion area and a margin fully examined under microscope

  11. Slide 11: Marketing Metvix - Galderma pre-launch preparations ongoing

    Marketing Metvix® – Galderma pre-launch preparations ongoing „ Several meetings held between Galderma and PhotoCure executives on three continents „ Several Steering Committee meetings held „ Galderma hired dedicated management resources „ Galderma task force established – More resources allocated t

  12. Slide 12: New indications in dermatology - Several possible indications

    New indications in dermatology – Several possible indications „ Positive data on acne – Pilot study completed – World wide acne market totals 1.7 bn USD per year „ Other areas of interest – Photoaging (skin rejuvenation) – Transplant patients – Wound healing (pilot study planned) – Viral diseases

  13. Slide 13: Hexvix preparation

    Hexvix® preparation Hexyl aminolevulinate powder + Phosphate buffer saline 50 mL ± Hexvix® solution - Instilled 1 hour in the bladder - Start cystoscopy within 30 minutes

  14. Slide 14: Hexvix in bladder cancer - positive results in phase II clinical trial

    Hexvix® in bladder cancer – positive results in phase II clinical trial Four times more patients with CIS lesions detected (CIS = Carcinoma in Situ) Hexvix® White light 12 / 13 92% 3 / 13 23% Patients have one or more CIS lesions

  15. Slide 15: Hexvix - phase III program ongoing

    Hexvix® – phase III program ongoing „ Europe – Enrolment in first clinical phase III study completed - Interim data confirm the positive phase II results – One additional study initiated „ USA – Investigational New Drug status obtained – Phase III studies initiated „ First marketing application plan

  16. Slide 16: Hexvix - pre-marketing activities ongoing

    Hexvix® – pre-marketing activities ongoing „ Contract manufacturer selected „ Market research study completed „ Price and reimbursement preparations ongoing „ Out-licensing activities initiated – PhotoCure will at least retain the Nordic region

  17. Slide 17: Research and development - strong pipeline

    Research and development – strong pipeline ALA derivatives R&D opportunities (excluding dermatology and urology) „ Barrets oesophagus – clinical pilot study initiated „ Colo-rectal cancer – clinical pilot study initiated „ Lesions in mouth, pharynx and larynx „ Gynaecology (vulva, cervix, ovarian) „

  18. Slide 18: Research and development - Alpharadin for bone metastasis

    Research and development – AlpharadinTM for bone metastasis „ AlpharadinTM is being developed by Anticancer Therapeutic Inventions AS (ATI) – PhotoCure owns 6.6% of ATI – Share options to increase ownership to more than 60% „ AlpharadinTM – A bone metastasis-seeking radio pharmaceutical – A new conc

  19. Slide 19: PhotoCure - important milestones the next twelve months

    PhotoCure – important milestones the next twelve months As of May 2002 Metvix® „ Expand the number of clinics in the Nordic countries – 150 clinics with light sources „ Submit additional clinical data in Australia, France, Portugal & Holland „ File new drug application for BCC in the US „ Initiate c

  20. Slide 20: PhotoCure - important milestones the next twelve months

    PhotoCure – important milestones the next twelve months As of May 2002 Hexvix® „ Complete current ongoing phase III studies for bladder cancer detection „ File first marketing authorisation application for bladder cancer detection „ Start clinical pilot study on treatment of bladder cancer Benzvix®

  21. Slide 21: Financial Statements - Profit & Loss

    Financial Statements – Profit & Loss Three months ended Six months ended 30.06.2002 30.06.2001 All figures in NOK 1,000 30.06.2002 30.06.2001 4 594 529 Sales 8 291 931 6 2 061 Other revenues 130 2 686 4 601 2 590 Total operating revenues 8 422 3 617 1 028 5 545 Salaries & other pers. costs 4 874 10

  22. Slide 22: Financial statements - Balance sheet

    Financial statements - Balance sheet Figures in NOK 1,000 30.06.2002 31.12.2001 Fixed assets 11 413 3 935 Receivables 24 181 10 456 Securities 221 229 283 564 Cash and bank deposits 83 930 21 614 Total assets 340 752 319 569 Shareholders' equity 206 212 259 398 Long term liabilities 17 524 17 362 Cu

PhotoCure — Q2 2002 Earnings Presentation on 6ix